Company intelligence / Profile preview

GenVec

Gaithersburg, Maryland, United Statespitchbook.com ↗

Ownership: Public · GNVC
Development stage: Phase 1

Overview

GenVec was a pioneer in the development of adenoviral vector-based gene therapies and vaccines. Its lead program targeting pancreatic cancer failed a late-stage trial several years before its acquisition. The company’s proprietary AdenoVerse™ platform enabled the development of multiple therapeutic candidates across oncology and infectious diseases. Over 3,000 subjects received GenVec therapeutics or vaccines in global clinical trials. In January 2017, Intrexon acquired GenVec to expand its own gene delivery capabilities.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Gene therapy (adenoviral vectors)vaccines
Industry: Biotech

Drug pipeline

1 asset

CGF166

Phase 1/2

Indications: Hearing loss, Balance disorders

Partnerships

Novartis – worldwide licensing/collaboration agreement on novel treatments using GenVec’s technology

Financials

Market cap: $0
Total revenue: $114K
Enterprise value: $-3.7M

Beyond the preview

Go deeper on GenVec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenVec.

Explore the full profile